796 related articles for article (PubMed ID: 29569310)
1. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
[TBL] [Abstract][Full Text] [Related]
3. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
4. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
5. AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer.
Yin L; Ye Y; Zou L; Lin J; Dai Y; Fu Y; Liu Y; Peng Y; Gao Y; Fu Y; Qi X; Deng T; Zhang S; Li X
J Exp Clin Cancer Res; 2023 Aug; 42(1):204. PubMed ID: 37563661
[TBL] [Abstract][Full Text] [Related]
6. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
[TBL] [Abstract][Full Text] [Related]
7. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
8. Molecular events in neuroendocrine prostate cancer development.
Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
10. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
[TBL] [Abstract][Full Text] [Related]
11. Cellular plasticity and the neuroendocrine phenotype in prostate cancer.
Davies AH; Beltran H; Zoubeidi A
Nat Rev Urol; 2018 May; 15(5):271-286. PubMed ID: 29460922
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
13. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
Coutinho I; Day TK; Tilley WD; Selth LA
Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
17. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract][Full Text] [Related]
19. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract][Full Text] [Related]
20. Emerging Variants of Castration-Resistant Prostate Cancer.
Vlachostergios PJ; Puca L; Beltran H
Curr Oncol Rep; 2017 May; 19(5):32. PubMed ID: 28361223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
